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Active Immunization of Japanese Quail Hens with a Recombinant Chicken
Inhibin Fusion Protein Enhances Production Performance1
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K. G. KOUSOULAS,† and W. C. FIORETTI‡
*Applied Animal Biotechnology Laboratories, Department of Poultry Science, Louisiana Agricultural Experiment Station,
Louisiana State University Agricultural Center, Baton Rouge, Louisiana 70803, †Gene Probe and Expression Laboratory,
Department of Veterinary Microbiology and Parasitology, School of Veterinary Medicine, Louisiana State University,
Baton Rouge, Louisiana 70803, and ‡AgriTech Laboratories, Inc., Coppell, Texas 75019
ABSTRACT
The effects of active immunization
against inhibin on production performance in female
Japanese quail (Coturnix coturnix japonica) were assessed
in two separate trials using an MBP-cINA521 fusion
protein as an immunogen. The fusion protein, MBPcINA521, consisted of the bacterial maltose binding
protein (MBP) and a truncated form of the mature asubunit of chicken inhibin (cINA521). MBP-cINAl521 was
constructed by: 1) excising a 521-bp PstI fragment from a
chicken inhibin a-subunit cDNA (cINA6; gift of P. A.
Johnson), 2) cloning this fragment, which encodes all but
the first 11 amino acid residues of the mature a-subunit,
into the pMal-c2 vector of the MBP fusion expression
system, and 3) expressing the fusion protein (MBPcINA521) from the Escherichia coli and purifying it using
affinity chromatography. In each trial, quail were
randomly and equally assigned to one of two injection
treatments as follows: 1) MBP-cINA521 in Freund’s
adjuvant, or 2) Freund’s adjuvant (vehicular controls;
CON). All immunizations were given subcutaneously
and Freund’s complete and incomplete adjuvant were
used for primary and booster injections, respectively.
In Trial 1, birds were given a primary challenge of 0.2
mg MBP-cINA521 per bird at 25 d of age, followed by
booster immunizations (0.1 mg MBP-cINA521 per bird)
at 33, 40, 47, 54 and 61 d of age and every 35 d
thereafter. The CON birds received vehicular immunizations at the same time intervals. In Trial 2, birds treated

with MBP-cINA521 received a primary challenge of 0.2
mg MBP-cINA521 per bird at 26 d of age, followed by
booster immunizations (0.1 mg MBP-cINA521 per bird)
using the same schedule as that used in Trial 1, with the
exception that no boosters were given after 61 d of age.
The CON birds received vehicular immunizations at the
same time intervals.
Collection of production performance data was initiated coincident with the laying of the first egg in each
trial (i.e., beginning at 41 and 44 d of age for Trials 1 and
2, respectively) and continued for 30 1-wk periods of
lay. Combined data from Trials 1 and 2 indicated that
the mean – SE age at first egg lay was markedly
decreased (P < 0.005) in MBP-cINA521-treated quail (53.4
–0.9 d of age) when compared to the CON (57.6 –1.3 d
of age). Likewise, the mean – SE age at 50% egg
production was reduced (P < 0.03) in quail immunized
against inhibin (65.4 – 2.1 d of age) when compared to
the CON (77.6 – 4.7 d of age). Total hen-day egg
production was also higher (P < 0.05, Trial 1; P < 0.01,
Trial 2) in MBP-cINA521-treated quail (88.7 –1.4%, Trial
1; 90.1 – 1.2%, Trial 2) than in the CON birds (81.9 –
2.9%, Trial 1; 73.6 – 6.5%, Trial 2). Collectively, these
findings provide evidence that inhibin immunoneutralization accelerated puberty and enhanced hen-day egg
production during a 30-wk period of egg lay in Japanese
quail.

(Key words: Japanese quail, inhibin, immunoneutralization, laying)
1998 Poultry Science 77:894–901

INTRODUCTION
The existence of the hormone inhibin was first
postulated more than 60 yr ago (McCullagh, 1932), yet

its chemical isolation was only recently achieved
(Miyamoto et al., 1985; Robertson et al., 1985). Inhibin
and activin are dimeric glycoproteins that share a
common a-subunit (Chen, 1993). Inhibin is comprised of
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Abbreviation Key: cINA521 = a truncated form of the mature asubunit of chicken inhibin; CON = control; FSH = follicle-stimulating
hormone; HDEP = hen-day egg production; Histag-cINA521 = vector
encoding the recombinant polyhistidine-tagged fusion protein; IPTG =
isopropyl-B-D-thiogalactoside; MBP = maltose binding protein.
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a specific a-subunit and one of two related b-subunits,
whereas activin is a hetero- or homodimer of two bsubunits (Rivier et al., 1987; de Jong, 1988; Ying, 1988;
Risbridger et al., 1990). Primarily produced by the
gonads, these two peptide hormones (inhibin and
activin) exert opposite physiological effects on the
control of pituitary follicle-stimulating hormone (FSH)
secretion. Inhibin appears to depress, whereas activin
stimulates, FSH secretion from the pituitary in both the
basal and stimulated states (Vale et al., 1988). Excellent
reviews on the isolation, production, assay, and biological actions of mammalian inhibin are available (see
Rivier et al., 1987; de Jong, 1988; Ying, 1988; Risbridger et
al., 1990).
Inhibin functions as an inhibitory feedback regulator
of pituitary secretion of FSH, however it appears to also
function in an autocrine or paracrine manner (Woodruff
et al., 1990; Findlay 1993) by acting as a competitive FSH
receptor antagonist. Because FSH plays an essential role
in the recruitment and subsequent development of
ovarian follicles, a successful strategy to induce hyperovulation in mammalian species has been the development of methods to neutralize endogenous inhibin
activity.
Immunoneutralization of inhibin has been associated
with increased ovulation rates in many mammalian
species, including cattle, sheep, pigs, and rats (Forage et
al., 1987; Findlay et al., 1989; Rivier and Vale, 1989;
Brown et al., 1990; King et al., 1990; Mizumachi et al.,
1990; Wrathall et al., 1990; Glencross et al., 1992; Scanlon
et al., 1993). A variety of inhibin-based antigens have
been used as vaccines in these studies. Accelerated
ovulation rates found in mammals vaccinated with
antigenic inhibin preparations is likely a consequence of
elevated plasma FSH levels (Culler and Negro-Vilar,
1988; Rivier et al., 1988; Vale et al., 1988; Martin et al.,
1991), which leads to enhanced ovarian follicular
development. Despite conflicting data on how levels of
FSH fluctuated during the ovulatory cycle, in all cycling
mammals studied, immunoneutralization of endogenous
inhibin has generally enhanced ovarian follicular development and ovulation rate, regardless of the antigen
used or the species challenged.
Although the control of follicular recruitment and
development within the ovary of the hen is poorly
understood, pituitary gonadotropin involvement has
been proven (Bahr and Johnson, 1984; Johnson, 1986),
and a role for inhibin in the control of avian
gonadotropin secretion and follicular development is
becoming increasingly apparent (see reviews of Johnson,
1993, 1997). Inhibin likely exerts parallel physiological
roles in follicular recruitment and development in fowl
to those documented in mammals. However, in birds,
involvement of inhibin in the control of ovulation rate
may (Akashiba et al., 1988; Tsonis et al., 1988; Johnson et

3New

England Biolabs, Beverly, MA 01915.
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al., 1993) or may not (Johnson et al., 1993; Wang and
Johnson, 1993a) be through suppression of pituitary FSH
secretion.
The effects of inhibin immunoneutralization on egg
production in avian species await investigation. Such an
assessment, however, has been made possible by the
recent cloning and sequencing of a cDNA encoding the
a-subunit of chicken inhibin by Wang and Johnson
(1993b).
Herein, a cDNA of the mature a-subunit of chicken
inhibin (from cINA6; gift of P. A. Johnson, Cornell
University, Ithaca, NY 14953) was digested with PstI to
produce a truncated DNA fragment that codes for 102 of
113 amino acids of the mature a-subunit (521 bp;
cINA521). cINA521 was then expressed as a fusion
protein with the Escherichia coli maltose binding protein
(MBP-cINA521) and used as an immunogen in female
Japanese quail to assess changes in reproductive performance. Plasma immunological responses of the MBPcINA521-treated birds vs control-treated birds were also
compared. Coturnix were chosen for study because their
reproductive physiology, from the standpoint of the
ovulatory process, is remarkably similar to that of eggtype chickens. This similarity is one of the many reasons
why Coturnix serve as the bird of choice (pilot model)
for extrapolation of research findings to the larger
domestic fowl (such as chickens and turkeys) (See
reviews of Kovach, 1974; Mills and Faure, 1992; Aggrey
and Cheng, 1994; Jones, 1996).

MATERIALS AND METHODS

Cloning and Expression of
Recombinant MBP-cINA521
The fusion protein, MBP-cINA521, consisted of MBP
and a truncated form of the mature a-subunit of chicken
inhibin. It was constructed by excising from a chicken
inhibin a-subunit cDNA (cINA6; gift of P. A. Johnson) a
521-bp PstI fragment encoding all but the first 11 amino
acid residues of the mature a-subunit (cINA521) and
cloning it into the pMal-c2 vector of the MBP fusion
expression system.3 Escherichia coli containing the recombinant plasmid were cultured at 37 C in LB broth
containing 2 g/L glucose and ampicillin (50 mg/mL).
Cultures were grown to an optical density of 0.5 at 600 nm.
Expression of the MBP-cINA521 fusion protein was
induced by addition of isopropyl-B-D-thiogalactoside
(IPTG) at a final concentration of 0.3 mM, which causes
derepression of the bacterial Tac promoter. Following
induction with IPTG, cells were incubated (37 C) for an
additional 3 h and then harvested by centrifugation at
4,000 · g for 20 min (supernatant discarded). Cells were
then resuspended (50 mL/L culture) in column buffer (20
mM Tris-HCL, pH 7.4; 200 mM NaCl; 1 mM EDTA) and
frozen overnight.
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Purification of Recombinant MBP-cINA521
Bacterial lysis was accomplished by sonication of the
thawed cell suspension (see above) using a Sonifier 450.4
Sonication was conducted on ice for 14 min in seven
2-min pulses. Cell debris was removed by centrifugation
(9,000 g for 30 min). The supernatant (containing MBPcINA521) was diluted (1:5) in column buffer and applied to
an affinity column of amylose/agarose resin. Unbound
proteins were washed from the resin overnight with
column buffer. MBP-cINA521 fusion protein was subsequently eluted from the amylose/agarose resin with 10
mM maltose in column buffer. Eluted fractions (8 mL)
were evaluated for protein content by measurement of
optical density at 280 nm. Proteins in the peak fractions
were characterized by fractionation by SDS-PAGE
(Laemmli, 1970) and visualized using a Coomassie stain.
The predicted molecular weight of the MBP-cINA521
fusion protein was approximately 56 kDa. Fractions
containing the MBP-cINA521 fusion protein were pooled
and the protein concentration was determined using the
Coomassie Plus Protein Assay5 with BSA as the protein
standard.

Development of Histag-cINA521 Fusion
Protein and ELISA Analysis of
Plasma Antibody Titers
To gain evidence of inhibin immunoneutralization,
plasma immunological responses of representative MBPcINA521- vs control (CON)-treated birds were compared.
In quail, blood sampling is a most stressful event. It
invariably interferes with egg laying and can be lethal.
Therefore, we chose not to blood sample the birds during
laying in either trial (see Vaccination Treatments, below).
Furthermore, because the Histag-cINA521-based ELISA
(described below) was not developed until after the
conclusion of Trial 1, we waited until the end of Trial 2 to
collect plasma from subject animals. Although it was
likely that titers to the immunogen would be diminished
at the conclusion of this trial, particularly as booster
injections were discontinued after 61 d of age, we
reasoned that demonstration of even a small immunological response would give evidence of a mechanism of
action and was, thus, an important part of our experiments.
We initially attempted to characterize the presence and
specificity of the hen’s humoral immune response to MBPcINA521 using Factor Xa cut MBP-cINA521 on Western
immunoblots. Although antibodies in the plasma of quail
treated with the immunogen showed a positive and
specific response to the inhibin fragment and MBP, we

4Branson Ultrasonics Co., Danbury, CT 06810.
5Pierce, Rockford, IL 61105.
6Xpress System, Invitrogen Co., Carlsbad, CA 92008.
7Sigma-Aldrich, St. Louis, MO 63160.
8Tecan US Inc., Research Triangle Park, NC 27709.

were unable to produce publication-quality results, even
after repeated attempts (data not shown). We believe this
is due to the fact that, because anti-quail secondary
antibodies were not available commercially, we were
compelled to use anti-chicken secondary antibodies,
which probably have lower affinity to quail immunoglobulins. Still wishing to determine whether an
immunological response to inhibin was generated by our
MBP-cINA521 treatment, we decided to construct a solid
phase immunoassay (ELISA). To do so, the 521-bp PstI
fragment from the cDNA encoding the a-subunit of
chicken inhibin was cloned into the pTrcHis vector for the
expression of a polyhistidine-tagged fusion protein.6 The
vector encoding the recombinant polyhistidine-tagged
fusion protein (Histag-cINA521) was expressed in E. coli
and Histag-cINA521 was isolated using immobilized metal
affinity chromatography under denaturing conditions (8
M urea). The isolated fusion protein was characterized by
SDS-PAGE and protein concentration determined using
the Coomassie Plus Protein Assay (data not shown). The
Histag-cINA521 fusion protein was then used to develop
our ELISA (see below) for testing for the presence of
antibody titers directed specifically against the truncated
a-subunit of chicken inhibin (cINA521) and not the entire
fusion protein (MBP-cINA521). The latter contains the
highly antigenic bacterial MBP.
Our ELISA was a modification of a protocol previous
described by Rejman et al. (1989). Specifically, the HistagcINA521 fusion protein was the antigen coated onto each
well of a 96-well microtiter plate (250 mg per well in
carbonate buffer, pH 9.6). All wells were blocked for
nonspecific binding with 1· PBS (140 mM NaCl, 1.5 mM
KH2PO4, 8.0 mM Na2HPO-7 H20, 2.7 mM KCl; pH = 7.4)/
Tween-20 (0.05%) + 1% BSA for 1 h at room temperature.
At the end of the study, representative birds (n = 5) from
each group (CON- and MBP-cINA521-treated) were bled
and plasma were obtained following centrifugation.
Plasma antibody samples were serially diluted to 1:250, 1:
500, 1:1,000, 1:2,000, 1:4,000, and 1:8,000 in PBS-Tween-20
+ 1% BSA. Each dilution in duplicate was applied into
wells coated with the Histag-cINA521 fusion protein and
incubated for 2 h at room temperature. Alkaline phosphatase conjugated rabbit anti-chicken IgG7 diluted 1:5,000
was added to each well and incubated for 1 h at room
temperature. The soluble substrate p-nitrophenyl phosphate7 was added into each well and color allowed to
develop for 45 min. The optical density of each well at 405
nm was measured using the SLT Rainbow Microplate
Reader.8

Animals and Husbandry
Female Japanese quail (Coturnix coturnix japonica)
hatched from a randombred line of birds maintained at
the Louisiana State University Department of Poultry
Science were used in the present study. In each trial (see
Vaccination Treatments, below), approximately 150 chicks
were removed from the incubator on Day 17 of incubation,
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leg-banded, and transferred in mixed-sex groups of 50 to
each of three decks of a Petersime 2S-D brooder battery9
modified for quail. Initial brooding temperature was 37.8
C with a weekly temperature decline of 2.8 C until an
ambient temperature of 23.9 to 26.7 C was achieved. A
quail starter ration (28% CP, 2,800 kcal ME/kg) and water
were supplied for ad libitum consumption throughout the
growing period (until 6 wk of age). Adults consumed a
laying ration (21% CP, 2,750 kcal ME/kg) and water ad
libitum. During the brooding period, birds were housed
under continuous dim light (22 lx). At 5 wk of age, a 14 h
light (280 to 300 lx): 10 h dark cycle was used to stimulate
egg lay in adult quail. Lights-on occurred at 0500 h; daily
maintenance and feeding chores were done at the same
time each day (0900 h).

Vaccination Treatments
At 25 and 26 d of age (Trials 1 and 2, respectively), birds
were wing-banded and sexed. Females were subsequently
housed in individual laying cages by equal and random
assignment to one of two injection treatments (Trial 1, 25
birds per treatment; Trial 2; 24 birds per treatment) as
follows: 1) MBP-cINA521 in Freund’s adjuvant, or 2)
Freund’s adjuvant (vehicular controls; CON). All injections (1.0 mL, primary injections; 0.5 mL, boosters) were
given subcutaneously along the dorsal midline at the level
of the scapulae and Freund’s complete and incomplete
adjuvant were used for primary and booster injections,
respectively (see below). Less than 2% of the birds
developed Freund’s-related reactions at the injection site.
In Trial 1, MBP-cINA521-treated birds were given a
primary immunization (0.2 mg MBP-cINA521 per bird) at
25 d of age, followed by booster injections (0.1 mg MBPcINA521 per bird) at 33, 40, 47, 54 and 61 d of age and every
35 d thereafter. The CON birds received vehicular
injections at these same time intervals. In Trial 2, MBPcINA521-treated birds received a primary immunization
(0.2 mg MBP-cINA521 per bird) at 26 d of age, followed by
booster injections of equivalent concentration and times of
administration as used in Trial 1, with the exception that
no boosters were given after 61 d of age. The CON birds
received vehicular injections at these same time intervals.

Variables Measured and
Statistical Analyses
Collection of production performance data was initiated coincident with the laying of the first egg in each
trial (i.e., beginning at 41 and 44 d of age for Trials 1 and 2,
respectively) and continued for 30 1-wk periods of lay.
Daily hen-day egg production (HDEP) and mortality
measures were recorded during this time. In addition,
average age at first egg and age at which hens reached 50%
egg lay were calculated for each injection treatment group
(CON vs MBP-cINA521) within a trial.

9Petersime

Incubator Co., Gettysburg, OH 45328.
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Within a trial, HDEP data were subjected to a one-way
ANOVA which incorporated a completely randomized
design with a split-plot arrangement of treatments. The
main plot consisted of the two injection treatments (CON
vs MBP-cINA521) and the 30 laying periods of 7 d each
comprised the split. In addition, average age at first egg
lay and age at which hens reached a rate of 50% egg
production were calculated for each treatment group.
Injection treatment differences in these two indices of
puberty were assessed by a two-way ANOVA using a
randomized block design RBD in which trials were
considered as blocks (replications). For the ELISA data,
injection treatment differences were detected at each
plasma serial dilution tested using a one-way ANOVA
within a completely randomized design.

RESULTS

Production and Characterization of
Recombinant MBP-cINA521
The SDS-PAGE analyses of the expressed and purified
MBP-cINA521 are shown in Figure 1 (only column
fractions 1, 5, 8, 11, 14, 16, and 31 were chosen for
illustrative purposes). The MBP-cINA521 fusion protein,
as identified by its apparent molecular weight of 56.6 kDa,
was present in several fractions. Examples of protein
peaks are represented by fractions 11, 14, and 16. As
expected, the fusion protein could not be detected in early
(e.g., prepeak fractions 1, 5, and 8) or late (e.g., postpeak
fraction 31) eluants. The SDS-PAGE analysis of pooled
peak protein fractions treated with Factor Xa protease
identified two additional protein bands with the approximate molecular weights of 43.8 and 12.8 kDa, corresponding to the apparent molecular weights of MBP and the asubunit fragment of chicken inhibin, respectively. Traces
of the entire MBP-cINA521 fusion protein was also
identified, presumably due to incomplete proteolytic
digestion. Extraneous proteins present in eluted and
pooled fractions are likely bacterial protein contaminants
present in low concentrations (Figure 1).

Immune Responses Following Active
Immunization Against MBP-cINA521
Histag-cINA521 was expressed in E. coli and purified
under denaturing conditions using affinity chromatography. The SDS-PAGE characterization of the purified
fractions showed a single prominent band with an
apparent molecular weight of 15.4 kDa, in keeping with
the predicted molecular weight of the fusion protein (data
not shown). The ELISA analyses demonstrated the
presence of antibodies directed against the recombinant
inhibin fragment (Histag-cINA521) in the plasma of
representative MBP-cINA521-challenged birds but not in
CON plasmas (Table 1). Significant injection treatment
differences (range: P < 0.0005 to P < 0.02) existed at all
plasma serial dilutions tested.
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FIGURE 1. SDS-PAGE analysis of recombinant MBP-cINA521. Lane A: molecular weight markers [bovine serum albumin (66.2 kDa), ovalbumin
(45.0 kDa), bovine carbonic anhydrase (31.0 kDa), soybean trypsin inhibitor (21.5 kDa), lysozyme (14.4 kDa), apotinin (6.5 kDa)]; Lane B: representative
elution fractions of recombinant MBP-cINA521 from affinity column (fraction number indicated); Lane C: recombinant MBP-cINA521 treated with
Factor Xa protease, inhibin fragment (cINA521), MBP, and undigested fusion protein (MBP-cINA521) are indicated by arrows.

Production Performance Following
Immunoneutralization of MBP-cINA521

DISCUSSION

Although egg and shell quality measures (e.g., misshapen, checked, soft-shelled, and double-yolked eggs;
egg weight, and specific gravity) were not collected, our
subjective impression was that such variables were not
affected by treatment with MBP-cINA521. Livability was
also similar (data not shown) between the two treatment
groups in both trials.
The combined results of puberty data from Trials 1 and
2 showed that mean age at first egg lay and age at 50% egg
production were dramatically decreased (P < 0.005 and P
< 0.03, respectively) in immunized quail (Table 2).
Furthermore, total HDEP (Table 3; Figure 2) was higher (P
< 0.05, Trial 1; P < 0.01, Trial 2) in MBP-cINA521-treated
quail than in the CON birds.

A fusion protein, MBP-cINA521, consisting of the
bacterial maltose binding protein (MBP) and a truncated
form of the mature a-subunit of chicken inhibin
(cINA521) was constructed. This construction was accomplished by: 1) excising a 521-bp PstI fragment from a
chicken inhibin a-subunit cDNA, a digest fragment that
encoded all but the first 11 amino acid residues of the
mature a-subunit, 2) cloning this fragment into the
pMal-c2 vector of the MBP fusion expression system,
and 3) expressing, from E. coli, the fusion protein, MBPcINA521. The latter was purified using immunoaffinity
column chromatography and characterized using SDSPAGE.
Electrophoretic results demonstrated that the MBPcINA521 fusion had a molecular weight of approximately

TABLE 1. Mean – SE optical density measurements from ELISA analysis of antibodies directed against recombinant
Histag-cINA521 in serially diluted plasma taken from quail hens injected with either the vehicular control (CON)
or actively immunized against inhibin using MBP-cINA5211
Plasma dilution
Treatment2

N

1:250

1:500

1:1,000

1:2,000

1:4,000

1:8,000

CON
MBP-cINA521

5
5

0.139 – 0.029
0.461 – 0.049

0.101 – 0.018
0.309 – 0.047

0.082 – 0.011
0.214 – 0.040

0.061 – 0.006
0.137 – 0.026

0.051 – 0.004
0.093 – 0.012

0.039 – 0.002
0.063 – 0.006

1Histag-cINA521 = vector encoding the recombinant polyhistidine-tagged fusion protein. MBP-cINA521 = maltose-binding protein with a truncated
form of the mature a-subunit of chicken inhibin.
2Within each plasma dilution (columns), significant treatment differences exist (range in P values: < 0.0005 to 0.02).
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FIGURE 2. Mean weekly hen-day egg production (HDEP) of Trials 1
and 2. Percentage HDEP in quail hens actively immunized against
inhibin using MBP-cINA521 (ÿ) is compared to hens injected with the
vehicular control (o) from Trial 1 (upper graph) and Trial 2 (lower
graph).

56.6 kDa. Factor Xa cleavage of MBP-cINA521 resulted in
two distinct proteins. Estimation of their molecular
weights by SDS-PAGE was consistent with an interpretation that the heavier protein (approximately 43.8 kDa)
was MBP and the lighter protein (approximately 12.8
kDa) was the truncated chicken a-inhibin fragment,

cINA521. The molecular weight for MBP is 42.7 kDa. The
apparent molecular weight of cINA521 is in agreement
with the molecular weight reported for the mature asubunit (13.6 kDa; Wang and Johnson, 1993b), when
corrected for the loss in molecular weight that would be
attributed to the elimination of the first 11 amino acid
residues of the chicken a-subunit of inhibin.
Immunoneutralization of inhibin has been associated
with increased ovulation rates in heifers (Glencross et al.,
1992; Scanlon et al., 1993), sheep (Forage et al., 1987;
Findlay et al., 1989; Mizumachi et al., 1990; Wrathall et
al., 1990), gilts (Brown et al., 1990; King et al., 1990), and
rats (Rivier and Vale, 1989). Some of the antigens tested
in these studies included: recombinant DNA derived
inhibin a-subunit, synthetic peptide fragments of inhibin
a-subunit, and partially purified inhibin from follicular
fluid.
Herein, active immunization of quail using MBPcINA521 resulted in a marked reduction of the mean
ages at first egg lay and 50% egg production and it
increased total HDEP during a 30-wk period of lay in
two separate trials. To our knowledge, this is the first
report that immunoneutralization of inhibin positively
impacts female reproductive performance in an avian
species. Our production performance findings in the
quail are consistent with similar reports in mammals
(see above) that inhibin immunoneutralization has a
positive impact on ovulation rate.
Our studies were not designed to determine the
mode(s) of action by which active immunization against
inhibin influences egg lay in birds. Nevertheless,
previous studies suggest that inhibin acts at the pituitary
to suppress FSH secretion and may have a paracrine
function in the gonads by competing for FSH receptor
binding sites (Woodruff et al., 1990; Findlay, 1993).
Therefore, in mammals, and perhaps also in birds,
accelerated ovulation rates postvaccination with antigenic inhibin preparations can be explained as the
logical end result of elevated plasma FSH levels (Culler
and Negro-Vilar, 1988; Rivier et al., 1988; Vale et al.,
1988; Martin et al., 1991) or greater availability of

TABLE 3. Mean – SE hen-day egg production (HDEP)
during a 30-wk period of lay in quail injected with either
the vehicular control (CON) or actively immunized
against inhibin using MBP-cINA5211

TABLE 2. Mean – SE ages at first egg lay and at 50% egg
production in quail injected with either the vehicular control
(CON) or actively immunized against inhibin using MBPcINA521 (combined data, Trials 1 and 2)1

Treatment

Age at first egg

CON
MBP-cINA521

57.6 – 1.3A
53.4 – 0.9B

HDEP

Age at 50%
egg production

Trial

n

CON

77.6 – 4.7a
65.4 – 2.1b

1
2

25
24

81.9 – 2.9a
73.6 – 6.5A

(d)

a,bMeans within a column with no common superscript differ
significantly (P < 0.03).
A,BMeans within a column with no common superscript differ
significantly (P < 0.005).
1MBP-cINA521 = maltose-binding protein with a truncated form of
the mature a-subunit of chicken inhibin.

MBP-cINA521
(%)
88.7 – 1.4b
90.1 – 1.2B

a,bMeans within a row with no common superscript differ significantly (P < 0.05).
A,BMeans within a row with no common superscript differ
significantly (P < 0.01).
1MBP-cINA521 = maltose-binding protein with a truncated form of
the mature a-subunit of chicken inhibin.
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ovarian FSH receptors for binding with FSH. Either or
both of these conditions could lead to enhanced ovarian
follicular recruitment and development. It should be
noted that the inhibin-FSH relationship is not always
straightforward. However, despite conflicting data on
how levels of FSH fluctuated during the ovulatory cycle,
immunoneutralization of endogenous inhibin has generally enhanced ovarian follicular development and ovulation rate, in all mammals studied, regardless of the
antigen used or the species challenged.
The demonstration of a humoral immune response of
MBP-cINA521-treated birds to Histag-cINA521 is also in
keeping with the proposed mechanism of MBP-cINA521
active immunization as it relates to production performance. The presence of antibodies that recognized the
Histag-based recombinant inhibin in the plasma of MBPcINA521-challenged quail suggests that vaccination with
MBP-cINA521 produced an immunoneutralization of
inhibin’s endocrine or paracrine actions relative to FSH.
With the diminution of the negative influences of
inhibin on FSH, we suggest that maturation of eggs in
the follicular hierarchy was enhanced, which would
explain our observations of an early onset of puberty
and increased HDEP rates in birds vaccinated with
MBP-cINA521.
In conclusion, these studies demonstrated that active
immunization against inhibin in Japanese quail enhanced production performance. Japanese quail have
been selected for intensity of egg lay and serve as a
useful model for egg laying domestic fowl. Our ability
to enhance production performance in a species previously selected for intensity of egg laying suggests that
immunization against inhibin in domestic fowl could
produce similar results, particularly in the broiler
breeder, but perhaps also in the Single Comb White
Leghorn. Further studies of inhibin immunoneutralization will be required to determine the precise mechanism of action in avians as well as its usefulness to the
poultry industry.
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